All
Advancements in ophthalmology: A comprehensive look at the FDA's 2023 approvals
December 19th 2023Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.
Study: Fish-like genetic program used to turn human retinal cells into neurons
December 6th 2023Some animals have the built-in ability to regenerate retinal neurons by turning another retinal cell type called Müller glia into neurons. Researchers have been able to coax the human Müller glia into changing identity in the laboratory, which could serve as a potential source of new neurons to treat vision loss.
Neuro-ophthalmic adverse events associated with COVID-19 infection and vaccinations
December 3rd 2023Researchers conducted a large nationwide, population-based, retrospective cohort study to determine if there is an association between COVID-19 infection and vaccination with neuro-ophthalmic adverse events.
Outlook Therapeutics outlines regulatory path forward for ONS-5010
December 2nd 2023The company announced a resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trial.